Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib for leptomeningeal melanomatosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Apr 2013

Schäfer Niklas, Scheffler Björn, Stuplich Moritz, Schaub Christina, Kebir Sied, Rehkämper Claudia, Mack Frederick, Niehusmann Pitt, Simon Matthias, Greschus Susanne, Kuchelmeister Klaus, Herrlinger Ulrich, Glas Martin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Treatment Outcome
Share to Vemurafenib
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Meningeal Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Identifiers

PMID: 23460716
DOI: 10.1200/JCO.2012.46.5773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib for leptomeningeal melanomatosis.PMID 23460716Read ↗

FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity Read ↗

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.Semantic proximity Read ↗

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Melanoma brain metastases and vemurafenib: need for further investigation.Semantic proximity Read ↗

Melanoma: Time for adjuvant vemurafenib?Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.